Search

Your search keyword '"Takahashi, Kuniaki"' showing total 717 results

Search Constraints

Start Over You searched for: Author "Takahashi, Kuniaki" Remove constraint Author: "Takahashi, Kuniaki"
717 results on '"Takahashi, Kuniaki"'

Search Results

3. Geographic disparity of pathophysiological coronary artery disease characteristics: Insights from ASET trials

5. Determination of lipid-rich plaques by artificial intelligence-enabled quantitative computed tomography using near-infrared spectroscopy as reference

6. Rationale and design of the INVICTUS Registry: (Multicenter Registry of Invasive and Non-Invasive imaging modalities to compare Coronary Computed Tomography Angiography, Intravascular Ultrasound and Optical Coherence Tomography for the determination of Severity, Volume and Type of coronary atherosclerosiS)

7. Diagnostic concordance and discordance between angiography-based quantitative flow ratio and fractional flow reserve derived from computed tomography in complex coronary artery disease

9. Ten-year all-cause death following percutaneous or surgical revascularization in patients with prior cerebrovascular disease: insights from the SYNTAX Extended Survival study

10. Impact of Body Composition Indices on Ten-year Mortality After Revascularization of Complex Coronary Artery Disease (From the Syntax Extended Survival Trial)

11. Impact of chronic obstructive pulmonary disease on 10-year mortality after percutaneous coronary intervention and bypass surgery for complex coronary artery disease: insights from the SYNTAX Extended Survival study

12. Abstract 13674: Optimal Hounsfield Threshold for Lipid-Rich Plaque by Artificial Intelligence-Enabled Quantitative CT Using Near-Infrared Spectroscopy

13. Abstract 13665: Determination of Lipid-Rich Plaque by Artificial Intelligence-Enabled Quantitative Computed Tomography Using Near-Infrared Spectroscopy

14. 10-Year Follow-Up After Revascularization in Elderly Patients With Complex Coronary Artery Disease

16. Mortality 10 Years After Percutaneous or Surgical Revascularization in Patients With Total Coronary Artery Occlusions

17. Influence of Bleeding Risk on Outcomes of Radial and Femoral Access for Percutaneous Coronary Intervention: An Analysis From the GLOBAL LEADERS Trial

18. Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A Sub-Study from GLOBAL LEADERS)

19. Endothelial shear stress and vascular remodeling in bioresorbable scaffold and metallic stent

21. The impact of pre-procedure heart rate on adverse clinical outcomes in patients undergoing percutaneous coronary intervention: Results from a 2-year follow-up of the GLOBAL LEADERS trial

22. Association of Pulse Pressure With Clinical Outcomes in Patients Under Different Antiplatelet Strategies After Percutaneous Coronary Intervention: Analysis of GLOBAL LEADERS

23. DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI

24. Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study

25. TCT-142 Impact of Chronic Total Occlusions on Outcomes in the FAME 3 Trial

26. TCT-594 Diagnostic Performance of Optical Coherence Tomography-Based FFR Versus Single Angiography View-Based QFR for Pre- and Post-PCI Physiological Assessment

28. Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial)

29. Clinical Implication of Quantitative Flow Ratio After Percutaneous Coronary Intervention for 3-Vessel Disease

30. Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI

31. The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial

32. Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial

33. Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial

34. Angiography-Derived Fractional Flow Reserve in the SYNTAX II Trial: Feasibility, Diagnostic Performance of Quantitative Flow Ratio, and Clinical Prognostic Value of Functional SYNTAX Score Derived From Quantitative Flow Ratio in Patients With 3-Vessel Disease

35. A 30-Day Pooled Analysis of Acetyl Salicylic Elimination Trials (ASET) in Brazil and Japan: Synergy Stent with Prasugrel Monotherapy Without Aspirin

36. Prognostic impact of early aortic volume changes at hospital discharge in patients with acute type B aortic dissection

37. The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial

39. Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial

40. TCTAP A-046 A 30-Day Pooled Analysis of Acetyl Salicylic Elimination Trials (ASET) In Brazil and Japan: Synergy Stent With Prasugrel Monotherapy Without Aspirin

43. Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary Intervention

44. Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events

46. Prasugrel Monotherapy After Percutaneous Coronary Intervention With Biodegradable-Polymer Platinum-Chromium Everolimus Eluting Stent for Japanese Patients With Chronic Coronary Syndrome (ASET-JAPAN)

47. CRT-100.33 A 30-Day Pooled Analysis of Acetyl Salicylic Elimination Trials (ASET) in Brazil and Japan: Synergy Stent with Prasugrel Monotherapy Without Aspirin

49. TCT-14 A 30-Day Pooled Analysis of Acetyl Salicylic Elimination Trials (ASET) After PCI in Brazil and Japan: SYNERGY Stent With Prasugrel Monotherapy (10 mg or 3.75 mg)

Catalog

Books, media, physical & digital resources